《肿瘤瞭望》：CRPC是难治性疾病，目前有哪些比较有效的治疗手段？

　　David olmos Hidalgo教授：最重要的一个问题是，我们仍不知道如何鉴别出已形成的去势抵抗性前列腺癌（castration-resistant prostate ，CRPC）。如果我们有工具去分析，然后我们仍然会有更多的变异，以看到是否患者有这种改变，然后给予治疗。目前有些治疗可以治疗难治性前列腺癌，我们仍然需要了解到更多，获得更多数据，做更多的试验。

　　<Oncology Frontier>: Castration-resistant prostate cancer（CRPC）is a kind of refractory disease. At present， are there more effective means of treatment?

　　Prof. David olmos Hidalgo: The first thing is that we don’t know yet how to identify which castration-resistant prostate cancer is formed. This is the first question. If we have the tool for analyzing， then we still have more variation that to see whether the patient have this alteration or this should be more…that this is not the standard therapy， and this is the standard therapy.

　　Now， are these refractory castration-resistant prostate cancer can be only the fine? As the first-line or second-line treatment. We can know to select patient in this therapy. There are some therapies at this moment to treat refractory….. I mean I think we still need to learn a lot， to get more data， and do more trials.

　　《肿瘤瞭望》：目前，是否可以从生物标志物层面改善CRPC的治疗效果？

　　David olmos Hidalgo教授：我认为，我们接近了。有很多候选，但是我们需要一个候选，这是经过验证的，是可行的。更重要的是，选择更好的临床因素，即哪些患者是适用的，那就意味着10%的患者可能获得好的疗效。

　　<Oncology Frontier>: Now， can we improve the therapeutic effect of CRPC by the biomarker?

　　Prof. David olmos Hidalgo: I think we are near there. There are many candidates， but we need a candidate that is validated that it is producible， that can be simulate the clinical. The more important thing is selecting a better clinical factor which patient is well fitted or not， because if I have the factor to select， that means 10% of the patients might not be cause effective.

　　《肿瘤瞭望》：关于最小化前列腺癌去势治疗不良事件，您有什么良策？

　　David olmos Hidalgo教授：这是一个非常大的问题。我认为，建议之一是，存在的困难问题是去弄明白我们患者的差异。从长远看，有些是可以预防的。仍然有进程不清楚，但是通过密集血细胞计数监测患者骨密度、骨量丢失它是明确的。在有显著骨质丢失（如钙）的患者中，他们已经形成了严重的过程。

　　<Oncology Frontier>: Could you give some advises about minimizing the complications of androgen-deprivation therapy (ADT)?

　　Prof. David olmos Hidalgo: This is a very long question. I mean， one of the advises is that， there are difficult troubles to work out in patient that the difference in our patients. There are things you can prevent in long term， you have to stimulate the patient in cell cycles， to put them away. Be active that is going to help to get mass loss， but it is clear to monitor the patients for bone density， bone mineral loss by using dense cytometry. In patient that having significant loss of bone mass such as calcium， they have developed severe process.